United States, 28th Sep 2026 – Platinum Biolabs has announced the opening of a new facility in Texas, marking an expansion of its U.S.-based operations and supporting the company’s continued focus on supplying research chemicals, peptides, and chemical compounds for laboratory, analytical, and research applications.
The new Texas facility strengthens Platinum Biolabs’ domestic operations and fulfillment capabilities while supporting its approach to product documentation, quality control, traceability, and customer service. As a U.S.-based research chemical supplier, the company works with established supply and manufacturing partners that meet its internal requirements for quality, documentation, and consistency.
Platinum Biolabs has built its research supply model around transparency and documented quality-control procedures. Applicable products are supported by batch-specific analytical testing and documentation, including Certificates of Analysis (COAs) where available. Researchers can use the applicable documentation to review testing information associated with specific products and batches.
The company’s quality standards include batch-specific analytical testing, purity verification for applicable products, controlled lyophilization and packaging processes, sealed research-grade vials, lot and batch traceability, Certificate of Analysis documentation, and established storage and fulfillment procedures.
Rather than applying a single specification across its entire catalog, Platinum Biolabs notes that analytical specifications and reported results can vary by product and batch. Customers are therefore encouraged to refer to the applicable Certificate of Analysis for the specific testing information associated with the material they are evaluating.
This batch-level approach provides researchers with access to documentation connected to individual products and lots, supporting greater visibility throughout the research-material procurement process. The company’s team is also available to assist customers with questions regarding Certificates of Analysis, lot identification, product documentation, storage, and fulfillment.
The opening of the Texas facility also expands the company’s U.S.-based fulfillment infrastructure. Platinum Biolabs says its domestic operations are intended to support efficient fulfillment, responsive customer service, product traceability, and access to relevant batch documentation.
“Opening our Texas facility represents an important step in the continued development of Platinum Biolabs’ U.S.-based operations,” said Shashank Polanki. “Our focus is on providing researchers and laboratories with dependable access to research materials while maintaining transparency around documentation, quality-control procedures, product traceability, and fulfillment.”
Platinum Biolabs supports both individual research requirements and larger-volume laboratory procurement. The company offers volume-based pricing for research materials, with standard pricing available for one to two vials, a 5% discount for three to four vials, a 10% discount for five to nine vials, and a 15% discount for orders of 10 or more vials.
The company’s research-focused model is designed to serve laboratories, researchers, and institutions seeking materials for laboratory and analytical applications. Its U.S.-based operations provide a domestic point of fulfillment while its documentation practices are intended to give customers access to relevant information about specific research materials.
Platinum Biolabs also maintains a clear distinction between research materials and products intended for medical or consumer use. All products offered by the company are sold exclusively for research, laboratory, and analytical purposes. They are not intended for human or animal consumption and are not intended for the diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition.
The company further states that its website claims have not been evaluated by the U.S. Food and Drug Administration and that Platinum Biolabs does not represent its products as FDA-approved drugs. The company identifies itself as a research chemical supplier rather than a pharmacy, a compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, or an outsourcing facility registered under Section 503B.
With the opening of its Texas facility, Platinum Biolabs is expanding the infrastructure behind its U.S.-based research supply operations while maintaining an emphasis on documentation, quality-control procedures, and traceability. The company says purchasers remain responsible for ensuring that the acquisition, possession, handling, and use of research materials comply with applicable federal, state, and local laws and regulations.
Researchers and laboratories seeking additional information about Platinum Biolabs, its research materials, documentation, and fulfillment operations can visit the company’s website https://platinumbiolabs.com .
About Platinum Biolabs
Platinum Biolabs is a U.S.-based research chemical supplier providing peptides and chemical compounds for laboratory, analytical, and research applications. The company’s quality-focused approach includes batch-specific analytical testing, applicable purity verification, controlled packaging and lyophilization processes, lot and batch traceability, Certificates of Analysis where available, and established storage and fulfillment procedures. Platinum Biolabs operates on a research-use-only basis and does not offer its products for human or animal consumption.
Media Contact
Organization: Platinum Biolabs
Contact Person: Shashank Polanki
Website: https://platinumbiolabs.com/
Email: Send Email
Country: United States
Release id: 49500
The post Platinum Biolabs Opens New Texas Facility, Strengthening U.S. Research Supply Operations appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.
